Posts

Showing posts with the label Muckle-Wells Syndrome market outlook

Muckle-Wells Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Muckle-Wells Syndrome (MWS) is a rare autoinflammatory disorder clinically classified as one of the three forms of Cryopyrin-Associated Periodic Syndrome (CAPS). CAPS is a hereditary disorder that results from genetic mutations in the NOD-like receptor 3 (NLRP3) gene. These mutations lead to the overproduction of proinflammatory interleukin 1β (IL-1β), which is the underlying cause of CAPS symptoms. MWS is characterized by recurring episodes of fever, headache, urticarial rash, arthralgia, or arthritis that occur without a specific trigger. These episodes typically begin in early childhood, with a median age of onset at 0.8 years. 40% to 80% of individuals with MWS experience intense fatigue, which can lead to social isolation. In some patients, these episodes last more than 24 hours and can occur as frequently as 24 times per year. MWS patients at high risk for severe disease activity can be identified at the time of diagnosis. Female patients with hearing loss, musculoskeleta...

Muckle-Wells Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
 Muckle-Wells Syndrome (MWS) is a rare autoinflammatory disorder clinically classified as one of the three forms of Cryopyrin-Associated Periodic Syndrome (CAPS). CAPS is a hereditary disorder that results from genetic mutations in the NOD-like receptor 3 (NLRP3) gene. These mutations lead to the overproduction of proinflammatory interleukin 1β (IL-1β), which is the underlying cause of CAPS symptoms. MWS is characterized by recurring episodes of fever, headache, urticarial rash, arthralgia, or arthritis that occur without a specific trigger. These episodes typically begin in early childhood, with a median age of onset at 0.8 years. 40% to 80% of individuals with MWS experience intense fatigue, which can lead to social isolation. In some patients, these episodes last more than 24 hours and can occur as frequently as 24 times per year. MWS patients at high risk for severe disease activity can be identified at the time of diagnosis. Female patients with hearing loss, musculoskeletal s...